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CASE REPORT
Plastered in pustules
James Powell specialist registrar, dermatology, Jaideep Bhat consultant dermatologist, Stephen
Orpin consultant dermatologist
Dermatology Department, Solihull Hospital, Solihull B91 2JL, UK
An 87 year old woman presented with a non-itchy rash that
began three weeks ago on the abdomen. Since then it had spread
to most of her trunk, face, and lower limbs. She was not
systemically unwell.
Her medical history included atrial fibrillation, cerebrovascular
disease, hypertension, and an intertriginous reaction for which
oral terbinafine 250mg daily had been started three days before
the rash began. Current long term drugs included aspirin,
warfarin, alendronic acid, bisoprolol, calcium supplements,
candesartan, furosemide, loperamide, and omeprazole. She had
no known drug allergies.
On examination, large confluent patches and plaques of
oedematous erythemawere present especially on the trunk, face,
and lower limbs. The palms and soles were spared. Hundreds
of small non-follicular based pustules were seen within these
areas. No ulceration or blistering was seen.
Blood tests showed normal renal and liver function, C reactive
protein (31 mmol/L; normal 0-1.7), total white cell count (15.7
×109/L; 4.0-11.0), neutrophil count (13.6×109/L; 2.5-7.5),
lymphocyte count (1.36×109/L), eosinophil count (0.32×109/L;
0.04-0.44). Haemoglobin and platelet counts were within the
normal range.
A swab from a pustule showed no bacterial growth. Histological
analysis showed subcorneal pustules.
Terbinafine was stopped immediately and the patient was treated
with topical steroids and emollients. The rash began to resolve
within a week.
Questions
1What is the diagnosis in this case of generalised pustulosis?
2 What is the main differential diagnosis?
3 Can you name three other severe cutaneous drug reactions?
4 How would you manage this patient’s rash?
Answers
1 What is the diagnosis in this case of
generalised pustulosis?
Short answer
On the basis of the history and clinical and histopathological
findings the diagnosis is acute generalised exanthematous
pustulosis.
Long answer
Acute generalised exanthematous pustulosis is an adverse
cutaneous drug eruption in which many small sterile pustules
develop within large areas of erythema (figure), often within a
few days of starting to take a new drug.
Fig 1 Small sterile pustules within patches of erythema
More than 90% of cases are caused by a drug and the condition
is slightly more common in women than in men.1 2 The skin
reaction often arises rapidly (within hours) on the face, axillae,
or groin and then spreads to the rest of the body.1 The pustules
are small “pin head sized” (less than 5 mm), sterile, numerous,
and non-follicular; they arise on an oedematous erythema. The
eruption may be accentuated in the flexural areas. The mucous
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membranes are affected only rarely and usually only one site is
affected. Fever greater than 38°C often occurs around the onset
of the rash.3 The skin may itch or burn (or both). A peripheral
neutrophilia may be present. Just as the skin reaction begins
abruptly, resolution typically occurs rapidly after stopping the
responsible drug, with no other treatment needed.1
Complications are rare and tend to occur in people with other
comorbidities.1 An acute generalised exanthematous pustulosis
validation scoring system exists.4
Although regarded as an uncommon cutaneous drug eruption
its incidence may have been under-reported. Acute generalised
exanthematous pustulosis—a term first used in 1980—has been
known by various terms such as toxic pustuloderma, pustular
drug rash, and pustular psoriasiform eruption with leucocytosis,
and sometimes it may have been misclassified as generalised
pustular psoriasis.1
Drugs that are thought to be “highly associated” with the
development of this eruption are quinolones, aminopenicillins
(amoxicillin and ampicillin), terbinafine, sulphonamides,
chloroquine, hydroxychloroquine, diltiazem, and pristinamycin.1
Less strong associations have been documented with
antiepileptics, macrolides, non-steroidal anti-inflammatory
drugs, and corticosteroids.1 Very rarely acute generalised
exanthematous pustulosis may be induced by viral infections.1 2
Hypersensitivity to mercury has also been noted as a
precipitating cause.5
The timing of onset of the skin reaction in relation to first taking
the drug responsible varies. The median onset after taking an
antibiotic from the highly associated drug list is one day,
whereas for the other drugs in that list it is 11 days.1
Histological analysis of pustular lesions in acute generalised
exanthematous pustulosis typically shows subcorneal and or
intraepidermal pustules, a marked oedema of the papillary
dermis, a perivascular infiltrate rich in eosinophils, and single
cell necrosis of keratinocytes.2 4
The pathogenesis of this reaction is thought to involve drug
specific T cells that produce large amounts of interleukin 8,
which attract neutrophils.




Generalised sterile pustulosis of the skin can also occur in
generalised pustular psoriasis. This condition is a severe form
of psoriasis and can be triggered by tapering of systemic
corticosteroids, pregnancy, infections, and hypocalcaemia. The
patient may have a history of (worsening) psoriasis or it may
arise de novo.
It is difficult to differentiate between the two conditions
clinically. The pustules seen in acute generalised exanthematous
pustulosis are clinically indistinguishable from those seen in
generalised pustular psoriasis. Crucially, in acute generalised
exanthematous pustulosis, patients have usually started taking
a new drug. In addition, the pustules are more often seen in the
skin folds in acute generalised exanthematous pustulosis than
in generalised pustular psoriasis, which causes a more
generalised eruption that is more likely to affect the palms and
soles and is associated with arthritis in around 30% of cases.4
Furthermore, in acute generalised exanthematous, the onset and
resolution of the eruption and fever are more acute than in
generalised pustular psoriasis. Patients with generalised pustular
psoriasis are more likely to have a history of psoriasis and have
a risk factor for the development of this condition. Generalised
pustular psoriasis should be suspected in patients taking a β
blocker or angiotensin converting enzyme inhibitor because
these drugs are known to induce psoriasis, but are not thought
to be major players in the induction of acute generalised
exanthematous pustulosis.4
Another condition that should be considered if a patient presents
with subcorneal pustules on histological analysis is subcorneal
pustular dermatosis. In this condition, patients present with
flaccid, oval, pea sized pustules in the flexural areas and flexor
aspects of the limbs.5 The face is usually spared. A characteristic
finding is that only the lower half of the pustule contains pus,
with the upper part containing clear fluid. The condition is
benign but chronic, and dapsone is the treatment of choice.
3 Can you name three other severe cutaneous
drug reactions?
Short answer
Stevens-Johnson syndrome, toxic epidermal necrolysis, and
drug reaction with eosinophilia and systemic symptoms
(DRESS).
Long answer
Stevens-Johnson syndrome and toxic epidermal necrolysis are
part of a spectrum of conditions characterised by skin tenderness
and erythema that evolve into large areas of skin necrosis that
cause the epidermis to be sloughed off in sheets. Severe mucosal
erosions of the lips, mouth, nose, conjunctiva, and genitals occur
alongside the skin blistering. Patients are systemically unwell
often with fever, malaise, arthralgia, and myalgia. If skin
detachment involves less than 10% of the total body surface
area then the diagnosis is Stevens-Johnson syndrome.6 If 10-30%
skin detachment occurs then an overlap between
Stevens-Johnson syndrome and toxic epidermal necrolysis can
be diagnosed.6 If more than 30% skin detachment occurs then
the diagnosis is toxic epidermal necrolysis.6 Drugs commonly
associated with the development of these conditions include
sulphonamides, antimalarials, anticonvulsants, aminopenicillins,
non-steroidal anti-inflammatory drugs, and allopurinol. Patients
with human immunodeficiency virus infection and certain
autoimmune conditions seem to be at greater risk of developing
these conditions.
Symptoms of DRESS (drug reaction with eosinophilia and
systemic symptoms) typically develop two to six weeks after
the responsible drug is taken. A high fever develops, and the
initial skin reaction may be maculopapular but can progress to
erythroderma.5 Papules and pustules can develop. Initially, the
face, upper trunk, and extremities are usually affected. Facial
oedema is often present, and peripheral blood eosinophilia is
seen in 90% of cases.5 Adenopathy, arthritis, arthralgia, and
involvement of internal organs can occur. The liver is most
commonly affected, and a fatal fulminant hepatitis can develop.
Myocarditis, pneumonitis, nephritis, and thyroiditis can also
form part of the clinical picture. Treatment is usually with
systemic corticosteroids.5 A scoring system is available to help
the clinician decide if this syndrome is “definitely, probably,
possibly, or not present.” The system is based on features such
as fever, adenopathy, organ involvement, eosinophilia, and
resolution within 15 days.7
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4 How would you initially manage this
patient’s rash?
Short answer
Apply greasy emollients to the skin regularly and treat any
coexisting infections. Pay meticulous attention to fluid and
electrolyte balance, haemodynamic stability, and body
temperature. Stop any possible causative drugs immediately.
Long answer
The above measures will help stop progression of the skin
reaction, help prevent complications, and provide symptomatic
relief. Meticulous attention must be paid to fluid balance,
haemodynamic stability, electrolyte imbalances, and body
temperature. In all cases of widespread cutaneous eruptions well
informed, high quality, constant nursing care is extremely
important.
Systemic steroids are not usually needed to treat acute
generalised exanthematous pustulosis because the eruption
settles once the responsible drug is identified and stopped.
Topical care in patients with acute generalised exanthematous
pustulosis is very important. The regular application of a greasy
emollient such as white soft paraffin:liquid paraffin (50:50) is
essential to help maintain the skin barrier. Topical steroids may
also help resolve the eruption. Always seek an expert
dermatological opinion regarding diagnosis and management,
which are often not straightforward.
As this case shows, great care should be taken when prescribing
systemic drugs for rashes such as intertrigo in elderly patients
who have multiple comorbidities and are taking multiple drugs.
Topical treatments are usually effective. Terbinafine is not the
treatment of choice for candidiasis, which is often the cause of
intertrigenous eruptions.
Patient outcome
The pustular eruption fully resolved after terbinafine was
stopped. She has had no recurrences. Unfortunately, her
intertrigo continues to be bothersome and she is being followed
up to manage this.
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